共 36 条
- [21] Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida®) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI plus two NRTIs)[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 21 - 21Yakubova, E.Kravchenko, A.Shimonova, T.Bessarab, T.Sizova, N.Stepanova, E.Pokrovskaya, A.Kuimova, U.Kuznetsova, A.Radzikhovskaya, M.Pozdnyakova, L.Ulyanova, Y.Gusev, D.Yakovlev, A.Kovelenov, A.Inozemtseva, E.Baranovsky, S.Arsienko, R.Remeeva, J.Corritori, S.Savchuk, N.Dukes, I.Weichert, A.Richman, D.Murphy, R.
- [22] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors[J]. BLOOD, 2020, 136Risitano, AntonioRoth, AlexanderKulasekararaj, AustinPu, JeffreyNishimura, Jun-IchiWright, LilyanAppius, AnitaSostelly, AlexandreSreckovic, SashaVignal, CharlotteMunir, Talha
- [23] The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea[J]. Annals of Hematology, 2014, 93 : 33 - 42Jin Seok KimJune-Won CheongYeo-Kyeoung KimJinny ParkYeung-Chul MunHye Jin KangHyeon Gyu YiJe-Hwan LeeYang Soo KimHun-Mo RyooSung-Hyun KimHo Young KimJin Young KimDong-Gun LeeHoon-Gu KimHawk KimYoung-Don JooYoo Hong Min
- [24] The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea[J]. ANNALS OF HEMATOLOGY, 2014, 93 (01) : 33 - 42Kim, Jin SeokCheong, June-WonKim, Yeo-KyeoungPark, JinnyMun, Yeung-ChulKang, Hye JinYi, Hyeon GyuLee, Je-HwanKim, Yang SooRyoo, Hun-MoKim, Sung-HyunKim, Ho YoungKim, Jin YoungLee, Dong-GunKim, Hoon-GuKim, HawkJoo, Young-DonMin, Yoo Hong
- [25] Switching to bictegravir/ emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance - A phase IV randomized, open-label pilot study (PIBIK study)[J]. HIV MEDICINE, 2023, 24 : 681 - 683Iwuji, C.Waters, L.Milinkovic, A.Orkin, C.Fox, J.Post, F.Perry, N.Bruce, C.Dailey, N.To, Y.Bremner, S.Geretti, A. M.Churchill, D.
- [26] The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}[J]. TRIALS, 2023, 24 (01)Xu, MengzhuoZhang, XinYe, RunyuLiu, XuetingSun, LirongJia, ShanshanZhang, ZhipengLi, XinranWang, ZiqiongLiao, HangShi, RufengLiu, KaiWang, SiMeng, QingtaoChen, Xiaoping
- [27] The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}[J]. Trials, 24Mengzhuo XuXin ZhangRunyu YeXueting LiuLirong SunShanshan JiaZhipeng ZhangXinran LiZiqiong WangHang LiaoRufeng ShiKai LiuSi WangQingtao MengXiaoping Chen
- [28] Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of ≥300/mm3:: CPCRA 059[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (03) : 221 - 231Abrams, DIBebchuk, JDDenning, ETDavey, RTFox, LLane, HCSampson, JVerheggen, RZeh, DMarkowitz, NP
- [29] Plasma glucose monitoring and the subsequent HbA1c control in patients with type 2 diabetes on a basal supported oral therapy regimen in real life: subanalysis of the ALOHA study: a 24-week, prospective, open-label, multicenter, observational study[J]. Diabetology International, 2015, 6 (1) : 66 - 76Odawara M.Kadowaki T.Naito Y.
- [30] Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)[J]. Diabetes Therapy, 2021, 12 : 955 - 964Hiroshi NomotoChiho Oba-YamamotoYuka TakahashiJun TakeuchiSo NagaiHiroki YokoyamaShinji TanedaYoshio KuriharaShin AokiHiraku KamedaKyu Yong ChoAkinobu NakamuraTatsuya AtsumiHideaki Miyoshi